{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"The number of participants who experienced at least one grade 3 or higher adverse events are summarized below.","groups":[{"description":"Patients receive 240 mg nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive 480 mg nivolumab IV over 60 minutes on day 1 of cycle 9. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Nivolumab)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 390 days","title":"Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}